Trintellix (vortioxetine) NDC 55154-0257

NDC codes

FDA NDC Directory

Product NDC (as listed)55154-0257Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55154-0257Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55154-0257-8	55154025708	2430 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55154-0257-8)Marketed from Oct 2, 2013

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Trintellix
Generic name (nonproprietary): vortioxetine
Active ingredients: Vortioxetine hydrobromide — 20 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Cardinal Health 107, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 204447
Marketing start: Oct 2, 2013
Listing expires: Dec 31, 2027
Identifiers: Product ID 55154-0257_7b53e0ea-8161-474c-b623-734841128a9aSPL ID 7b53e0ea-8161-474c-b623-734841128a9aSPL set ID cb1e9df4-dd74-4073-9d78-bb55593dd000RxCUI 1439808, 1439810, 1790886, 1790890UNII TKS641KOAYUPC 0355154025783, 0355154025684

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N455154025708 followed by a unit qualifier and the quantity

Package 55154-0257-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 17, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults. TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults ( 1 , 14 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 204447

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 204447
Product	Strength	Form · route	Labeler	Product NDC
Trintellixvortioxetine	Vortioxetine hydrobromide 5 mg/1	Tablet, Film coatedOral	REMEDYREPACK INC.	70518-4483
Trintellixvortioxetine	Vortioxetine hydrobromide 10 mg/1	Tablet, Film coatedOral	REMEDYREPACK INC.	70518-4284
Trintellixvortioxetine	Vortioxetine hydrobromide 10 mg/1	Tablet, Film coatedOral	Cardinal Health 107, LLC	55154-0256
Trintellixvortioxetine	Vortioxetine hydrobromide 5 mg/1	Tablet, Film coatedOral	Takeda Pharmaceuticals America, Inc.	64764-720
Trintellixvortioxetine	Vortioxetine hydrobromide 10 mg/1	Tablet, Film coatedOral	Takeda Pharmaceuticals America, Inc.	64764-730
Trintellixvortioxetine	Vortioxetine hydrobromide 20 mg/1	Tablet, Film coatedOral	Takeda Pharmaceuticals America, Inc.	64764-750